Mycobacterium avium subsp. paratuberculosis Antigens Elicit a Strong IgG4 Response in Patients with Multiple Sclerosis and Exacerbate Experimental Autoimmune Encephalomyelitis

• Published in: Life (Basel, Switzerland) Vol. 13; no. 7; p. 1437
• Main Authors: Cossu, Davide, Tomizawa, Yuji, Yokoyama, Kazumasa, Sakanishi, Tamami, Momotani, Eiichi, Sechi, Leonardo A., Hattori, Nobutaka
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 25.06.2023; MDPI
• Subjects: Antibodies; Antibody response; Antigens; Autoimmune diseases; Encephalomyelitis; Epstein-Barr virus; Experimental allergic encephalomyelitis; experimental autoimmune encephalomyelitis; Heat shock proteins; heath shock protein 70; IgG4; Immunization; Immunoglobulin G; Immunoregulation; Inflammation; Lymphocytes T; Microorganisms; Multiple sclerosis; mycobacteria; Mycobacterium avium; Oligodendrocyte-myelin glycoprotein; Paratuberculosis; Pathogens; Patients; Peptides; Proteins; Signs and symptoms; Subgroups; United States > US; Italy; Japan; heath shock protein 70; IgG4; experimental autoimmune encephalomyelitis; mycobacteria; multiple sclerosis
• DOI: 10.3390/life13071437
• ISSN: 2075-1729

Neuroinflammation can be triggered by microbial products disrupting immune regulation. In this study, we investigated the levels of IgG1, IgG2, IgG3, and IgG4 subclasses against the heat shock protein (HSP)70533–545 peptide and lipopentapeptide (MAP_Lp5) derived from Mycobacterium avium subsp. paratuberculosis (MAP) in the blood samples of Japanese and Italian individuals with relapsing remitting multiple sclerosis (MS). Additionally, we examined the impact of this peptide on MOG-induced experimental autoimmune encephalomyelitis (EAE). A total of 130 Japanese and 130 Italian subjects were retrospectively analyzed using the indirect ELISA method. Furthermore, a group of C57BL/6J mice received immunization with the MAP_HSP70533–545 peptide two weeks prior to the active induction of MOG35–55 EAE. The results revealed a significantly robust antibody response against MAP_HSP70533–545 in serum of both Japanese and Italian MS patients compared to their respective control groups. Moreover, heightened levels of serum IgG4 antibodies specific to MAP antigens were correlated with the severity of the disease. Additionally, EAE mice that were immunized with MAP_HSP70533–545 peptide exhibited more severe disease symptoms and increased reactivity of MOG35–55-specific T-cell compared to untreated mice. These findings provide evidence suggesting a potential link between MAP and the development or exacerbation of MS, particularly in a subgroup of MS patients with elevated serum IgG4 levels.